Subsequently, S737F was included among the 177 variants that are considered to be responsive in vitro to elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) (https://pi.vrtx.com/files/uspi_elexacaftor_tezacaftor_ivacaftor.pdf, accessed on 26 February 2023) and included in the U.S. Food and Drug Administration (FDA) list of CFTR variants approved for CF treatment. The gene discussed is CFTR; the disease is cystic fibrosis.